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While iPSCs have created unprecedented opportunities for drug discovery, there remains uncertainty con-
cerning the path to the clinic for candidate therapeutics discovered with their use. Here we share lessons
that we learned, and believe are generalizable to similar efforts, while taking a discovery made using iPSCs
into a clinical trial.Phenotypic assays using mature human
cells derived from embryonic stem cells
(ESCs) (McNeish, 2004) and induced
pluripotent stem cells (iPSCs) (Grskovic
et al., 2011) enable researchers to study
disease-relevant phenotypes and provide
a rich discovery tool for candidate thera-
peutics (Bellin et al., 2012). Furthermore,
iPSCs have the potential for improving
the identification of drug targets and
candidate compounds as well as con-
tributing to the optimized selection and
stratification of trial participants. These
applications could lead to more efficient
clinical trials and reduced drug attrition
during the development process.
While employing iPSCs is clearly attrac-
tive, the novelty of the approach has left its
place in the drug discovery pipeline
uncertain. On one hand, experiments with
iPSCs can provide increased confidence
in the relevanceof amedicine toapatient’s
genetic makeup and human cellular
physiology, suggesting that they may be
more relevant to decision-making than
existing animal models. On the other, the
in vitro assays inwhich iPSCsaregenerally
deployed leave reasonable questions
concerning whether the mechanism of
disease and candidate therapeutic identi-
fied have relevance in vivo. This natural
and understandable tension leaves many
engaged in iPSC research uncertain con-
cerning the optimal path to the successful
initiation of a clinical trial based on their
discoveries. We reasoned it would there-8 Cell Stem Cell 17, July 2, 2015 ª2015 Elsevfore be useful to share our experiences
and generalizable learning from translating
a recent discovery made with iPSCs
to an approved clinical trial for ALS
patients (Wainger et al., 2014; Kiniskinis
et al., 2014) (https://clinicaltrials.gov/,
NCT# 02450552).
Recently, we showed that iPSC-
derived motor neurons produced from
ALS patients harboring SOD1 mutations
display reproducible, disease-relevant
phenotypes (Kiskinis et al., 2014; Wainger
et al., 2014.) These phenotypes included
hyperexcitability with increased sponta-
neous action potentials and reduced
survival (Wainger et al., 2014). More
specifically, motor neurons from ALS
patients displayed a reduced delayed-
rectifier potassium channel activity.
Further studies showed that this pheno-
type could be corrected by modulating
the Kv7.2/3 class of potassium channels.
Evidence that correcting motor neuron
physiology was protective came through
treatment with the approved antiepileptic
and Kv7.2/3 potassium channel agonist
ezogabine, which reduced neuronal
excitability and improved cell survival
(Wainger et al., 2014; Kiskinis et al.,
2014). The first important lesson we
learned from our desire to translate these
studies was that the use of gene editing
to correct the SOD1 mutation, and with
it the physiological changes we observed,
was critical in building confidence in our
findings.ier Inc.To date, the only approved medicine
available to ALS patients is Riluzole
(Rilutek, Sanofi). The exact mechanisms
by which Riluzole acts remain controver-
sial, but have been proposed to include
inhibition of Na+ channels and glutamate
activity (Bellingham, 2011). To date
many additional mechanisms of drug
action have been clinically evaluated in
ALS, with seven compounds demon-
strating positive phase 2 results. How-
ever, none of these seven have yet
delivered positive findings in a pivotal
phase 3 study. Thus, the identification of
novel targets for ALS, like Kv7.2/3, worthy
of being tested in the clinic remains sorely
needed.
From the perspective of GlaxoSmith
Kline (GSK), and likely other potential
industry partners, a key concern with
moving findings in ALS forward to the
clinic has been the historically unreliable
human translation of compounds evalu-
ated in the SOD1 mouse model (Perrin,
2014; Bellingham, 2011). In point of fact,
Riluzole was brought to market prior to
the development of this mouse model.
Several hypotheses have been advanced
concerning why discoveries from this
mouse perform poorly in the clinic. One
of the most reasonable is that given the
genetic heterogeneity of ALS, it could be
that features of disease in SOD1 patients
may not be central to disease progression
in individuals harboring mutations in
other genes. To determine how general
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Kv7.2/3 were, we examined motor neuron
physiology and response to ezogabine in
a larger cohort of controls and patients
harboring mutations in three distinct
genes linked to ALS: SOD1, C9orf72,
and FUS (Wainger et al., 2014). Our find-
ings from these studies demonstrated
similar physiological changes in the
distinct patient classes, which were each
rescued by ezogabine. Showing that the
target phenotype and drug response
were generalizable across patient forms
was compelling enough to many key
decision-makers to allow us to move
forward without drug testing in the SOD1
mouse model. Thus, while testing in
animal models may be indispensable in
some cases, we found that a higher pre-
mium was often placed on our data that
supported the notion that the therapeutic
approach proposed was valid to a
broader portion of the patient population.
Another key factor enabling our clinical
efforts was the relatively close alignment
between the assays we carried out
in vitro using iPSCs with emerging elec-
trophysiological measures being made
in the clinic. It has been shown using
transcranial magnetic stimulation and
threshold-tracking nerve conduction
studies that ALS patients have a more
excitable motor circuit and that the larger
this change in physiology the worse a
patient’s prognosis (Bae et al., 2013).
As a result, a clinical trial could be
readily designed that employed clinical
physiological measures to test the
hypothesis that ezogabine might reduce
motor circuit excitability in patients,
much as it did in iPSC-derived motor
neurons. In addition, we could propose
to use physiological measures as phar-
macodynamic biomarkers of ezogabine’s
impact on hyperexcitability, measuring
the effect of two doses of ezogabine rela-
tive to placebo. Our experience suggests
that carefully taking known in-patient
biomarkers of disease into consideration
when designing in vitro phenotypic
assays with iPSCs can pay substantial
dividends in later stages of translation. If
we had not aimed our studies at under-
standing the mechanistic underpinning
of a known patient phenotype, which
could be readily measured clinically, we
would have needed to pursue the time-
consuming and costly process of devel-
oping a biomarker ourselves.It is also worthy of note that our path to
the clinic was aided in part by good
fortune. A key driver of enthusiasm for
trialing ezogabine in ALS patients, which
was only partially in our control, was its
well-known chemical and pharmacolog-
ical properties as an approved drug. As
an efficacious drug for epilepsy that acts
through the opening of Kv7.2/3 channels,
we could rely on preexisting clinical evi-
dence that ezogabine engaged its target
in the brain with therapeutic effect. In the
absence of such data, expensive studies
of compound toxicity, bioavailability, and
in vivo half-life, likely coupled with addi-
tional cycles of chemical optimization
and further testing, would have been
needed before we could have considered
a clinical trial. Our own experience sug-
gests that many academic labs may find
expertise in these pharmacological tests
and medicinal chemistry either unavai-
lable or unaffordable. Thus if it is the
motivation of an academic investigator
to rapidly test their iPSC-derived hypo-
theses clinically, it may be advisable for
them to focus attention on libraries of
already approved drugs or compounds
that have made substantial progress in
the clinic. Furthermore, if several mole-
cules have been discovered with promise,
it clearly would be most pragmatic to
move forward using a compound with
stronger pharmacological data even if
another showed marginally better perfor-
mance in vitro.
In short, we found that the strong scien-
tific foundation we had produced using
iPSCs, a clear clinical question that could
be tested using an established biomarker,
and a compound with strong pharmaco-
logical properties were each essential
pieces in the puzzle of organizing partner-
ships between academics, clinicians,
patient advocacy groups, and industry
that were needed to mount a clinical trial.
The basic research supported by Boston
Children’s Hospital, Harvard, HHMI,
Target ALS, the ALS Association (ALSA),
and GSK enabled the assembly of a con-
sortium to fund the clinical study, which
included the Harvard Stem Cell Institute
(HSCI), Massachusetts General Hospital
(MGH), GSK, and ALSA. It was our expe-
rience that, as has recently been sug-
gested (Saha and Hogle, 2014), when a
large federation of scientists, physicians,
and drug development experts can be
assembled, many of the clinical and regu-Cell Stemlatory challenges to mounting a clinical
trial are more rapidly overcome.
Another critical accelerator of our study
was our ability to work with a preexisting
clinical research team. The Northeast
ALS (NEALS) Consortium together with
the MGH Neurological Clinical Research
Institute provided robust yet adaptable
infrastructure for the rapid translation to
a trial of the scale we proposed. Working
with a preexisting clinical network allowed
us to streamline the processes of devel-
oping the clinical trial protocol, trial
contracts, and essential measures for
subject safety monitoring and obtaining
the needed FDA IND exemption for
testing Retigabine in ALS patients. Inves-
tigators interested in advancing toward
the clinic would be well advised to famil-
iarize themselves with similar clinical
consortia operating in their indication of
interest and then to build strong enabling
relationships with such groups. If such a
group does not exist, our experience sug-
gests that energy expended to help orga-
nize one would be well allocated.
Another important and likely generaliz-
able lesson we learned while preparing
our trial design was that enthusiasm
from our funding partners for making the
needed investment was increased by
incorporating provisions for collecting
additional samples that would fuel future
basic research on ALS. A key component
of the ezogabine study is to derive hiPSC
lines from participants. This type of
parallel study represents a unique oppor-
tunity afforded by hiPSC research. It
seems highly probable that similar ap-
proaches would be viewed as valuable
by funders if implemented in other clinical
investigations for which highly reproduc-
ible hiPSC-based disease models have
been developed. We found that adopting
this strategy was motivating to our entire
consortium, which was eager to see
whether the patients enrolling in the clin-
ical trial reflected the biology of those
patients that originally drove initiation of
the study. The future availability of this
iPSC resource to the community will
mean that our clinical trial will become
‘‘evergreen.’’ It will allow investigators to
study correlations between patient out-
comes and in vitro phenotypes in motor
neurons or other cell types. In addition,
with the iPSC resource in hand, variation
in drug response could be investigated
mechanistically. If the trial is a success,Cell 17, July 2, 2015 ª2015 Elsevier Inc. 9
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evaluating compounds emerging from
future high-throughput screens for novel
Kv7.2/3 agonists. If our trial fails, these
iPSC could nonetheless be useful for
attempting to further stratify the patient
population, for testing additional thera-
peutics, or for trying therapeutic combina-
tions. Due to the substantial interest in the
iPSC resources, a key feature of the part-
nership agreement that serves as a foun-
dation of our trial is that it makes these
stem cells available for both basic and
commercial research following comple-
tion of the trial.
The combination of careful execution
and good fortune outlined above placed
us in position to file an Investigator-Spon-
sored IND-exemption request, which
has now been approved by the FDA
to evaluate ezogabine in a phase 2
multicenter, randomized, double-blind,
placebo-controlled study of neuronal
excitability in ALS subjects. Secondary
outcomes of the study will include tole-
rability and safety of ezogabine in ALS
patients. This trial will be conducted at
12 U.S. NEALS Consortia sites. Of note,
this program progressed from initial dis-
covery to phase 2a study initiation in
less than 2 years. We hope that outlining
what we feel were the key factors playing
important roles in the successful transla-
tion of ezogabine, both fortuitous and
carefully calculated, will be valuable to10 Cell Stem Cell 17, July 2, 2015 ª2015 Elsethose interested in taking their own dis-
coveries made with iPSCs to the clinic.
We recognize that the type of trial we
are undertaking and propose could be
useful in many other disease contexts,
though it is not without its complications
and potential limitations. For example,
there are substantial challenges to
reducing technical variability among
more than 100 iPSC lines made from pa-
tient samples collected at a dozen sites.
Even with iPSCs in hand, improved
processes will be needed to efficiently
and reproducibly differentiate, culture,
and analyzemotor neurons from this large
number of patients. Still, we are optimistic
that such challenges can be overcome
and that additional clinical trials will
emerge from the many studies of dis-
ease-relevant cell types being made
from hiPSCs (Grskovic et al., 2011). The
ever-expanding reporting of clinically
relevant phenotypes in hiPSC disease
models, as well as the pharmacological
correction of pathologic disease features
in these cells, is creating an exciting
environment for the development of new
medicines. As the reproducibility and
robustness of stem cell technologies
continues to improve so toowill their utility
in nominating hypothesis for clinical
testing. We believe that interest in hiPSC
technologies for applications in drug
research and development will continue
to grow and that these cells will eventuallyvier Inc.serve as surrogates for many clinical
phenotypes and perhaps even provide a
new form of companion diagnostic.
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